Corline Biomedical (CLBIO) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
16 Nov, 2026Executive summary
Q3 revenue was SEK 2.356M versus SEK 1.305M YoY; lower-than-expected orders drove a temporary sales slowdown and a net loss of SEK 4.774M.
Management sees growth from Kardium and new medical-device customers, targeting SEK ~200M revenue in 2030 from Kardium alone.
Financial highlights
Jan–Sep revenue was SEK 11.335M versus SEK 5.547M; net loss improved to SEK 8.711M from SEK 9.687M.
Q3 operating loss was SEK 4.052M versus SEK 3.359M; net loss was SEK 4.774M versus SEK 3.359M.
Q3 operating costs rose to SEK 6.440M from SEK 4.972M, reflecting higher raw-material and personnel costs, including consultants.
Cash and cash equivalents were SEK 29.869M at Sep 30, 2026, versus SEK 5.818M a year earlier; cash includes Kardium’s USD 1M loan.
Outlook and guidance
FY2026 revenue guidance is SEK 16M and EBITDA guidance is negative SEK 10M; Q4 sales are expected to return to H1 2026 levels.
FY2027 guidance is SEK 30M revenue with positive EBITDA, alongside a marginal cost increase versus 2026.
SEK ~200M revenue in 2030 is projected from the Kardium relationship alone, based on expected PFA growth and successful Globe product launch.
Latest events from Corline Biomedical
- Sales more than doubled in H1 2026, driven by Globe system expansion and strong cash flow.CLBIO
Q2 2026 - Record commercial sales and Kardium partnership drive growth and margin improvement.CLBIO
Q1 2026 - First US commercial use of CHS™ and strong financing set stage for 2026 growth.CLBIO
Q4 2025 - Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth.CLBIO
Q3 2025 - Growth depends on Kardium's US launch, with cost cuts improving results despite lower sales.CLBIO
Q2 2025 - Sharply reduced costs and strategic focus position Corline for growth and profitability by 2025.CLBIO
Q3 2024 - Revenue down, losses widened, but US launch and new projects drive future potential.CLBIO
Q2 2024 - Corline's Q1 2025 loss widens, but US market entry and strong clinical data drive optimism.CLBIO
Q1 2025 - 2024 saw heavy losses and restructuring, but Corline targets US growth with CHSTM-coated Globe®.CLBIO
Q4 2024